Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes…

By B. Coiffier, C. Thieblemont, E. Van Den Neste, G. Lepeu, I. Plantier, S. Castaigne, S. Lefort, G. Marit, M. Macro, C. Sebban and 4 more. Blood, 2010

1,403 citations recorded by the source corpus.

Subfields: Neurology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/563698c77518f370c25e4d932836cc805ecbea5c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. H. Tilly
2. M. Meignan
3. M. G. Silva
4. U. Vitolo
5. A. Jack
6. Peter W M Johnson
7. M. Ladetto
8. M. André

Citations in the corpus

• Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012, background): “Six to eight cycles of combination chemotherapy with CHOP plus eight doses of rituximab given every 21 days is the current standard [I, A] [41].”